These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35713866)

  • 21. Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and Other Coronaviruses: A Genome-wide Comparative Annotation and Analysis.
    Tarique M; Ahmad S; Malik A; Ahmad I; Saeed M; Almatroudi A; Qadah T; Murad MA; Mashraqi M; Alam Q; Al-Saleh Y
    Mol Cell Biochem; 2021 May; 476(5):2203-2217. PubMed ID: 33564990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now.
    Mittal N; Garg V; Bhadada SK; Katare OP
    Curr Drug Deliv; 2021; 18(3):289-296. PubMed ID: 32938349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
    Talasaz AH; Kakavand H; Van Tassell B; Aghakouchakzadeh M; Sadeghipour P; Dunn S; Geraiely B
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):249-259. PubMed ID: 32671601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
    Wang S; Sun Q; Xu Y; Pei J; Lai L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019.
    Hayden MR
    J Int Med Res; 2020 Jul; 48(7):300060520939746. PubMed ID: 32722979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential SARS-CoV-2 nonstructural proteins inhibitors: drugs repurposing with drug-target networks and deep learning.
    Azmoodeh SK; Tsigelny IF; Kouznetsova VL
    Front Biosci (Landmark Ed); 2022 Apr; 27(4):113. PubMed ID: 35468672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Therapeutic Journey of Potential Drugs Against COVID-19.
    Ali F; Hussain S; Zhu YZ
    Mini Rev Med Chem; 2022; 22(14):1876-1894. PubMed ID: 33845740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 and Cardiovascular Comorbidities.
    Müller-Wieland D; Marx N; Dreher M; Fritzen K; Schnell O
    Exp Clin Endocrinol Diabetes; 2022 Mar; 130(3):178-189. PubMed ID: 33157558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening Anti-inflammatory, Anticoagulant, and Respiratory Agents for SARS-CoV-2 3CL
    Caires Silveira E
    Rev Invest Clin; 2022 Jan; 74(1):31-39. PubMed ID: 34495950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinguishable Immunologic Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic Individuals.
    Zhao R; Sun Y; Zhang Y; Wang W; Wang S; Wang C; Liu J; Gao L; Hu Z; Fei J; Hou X; Zheng H; Chen L
    Mediators Inflamm; 2020; 2020():6914878. PubMed ID: 33061829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes and COVID-19: Global and regional perspectives.
    Jeong IK; Yoon KH; Lee MK
    Diabetes Res Clin Pract; 2020 Aug; 166():108303. PubMed ID: 32623038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential Drug Strategies to Target Coronaviruses.
    Sarkar K; Sil PC
    Adv Exp Med Biol; 2021; 1352():111-124. PubMed ID: 35132597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19.
    Zhu Z; Zhang S; Wang P; Chen X; Bi J; Cheng L; Zhang X
    Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34718395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A consideration of publication-derived immune-related associations in Coronavirus and related lung damaging diseases.
    Geifman N; Whetton AD
    J Transl Med; 2020 Aug; 18(1):297. PubMed ID: 32746922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.